|
Gene: ATP5S |
Gene summary for ATP5S |
Gene summary. |
Gene information | Species | Human | Gene symbol | ATP5S | Gene ID | 27109 |
Gene name | distal membrane arm assembly component 2 like | |
Gene Alias | ATP5S | |
Cytomap | 14q21.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q99766 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27109 | ATP5S | S014 | Human | Liver | HCC | 1.01e-08 | 4.75e-01 | 0.2254 |
27109 | ATP5S | S015 | Human | Liver | HCC | 3.14e-10 | 6.90e-01 | 0.2375 |
27109 | ATP5S | S016 | Human | Liver | HCC | 2.36e-12 | 5.12e-01 | 0.2243 |
27109 | ATP5S | S027 | Human | Liver | HCC | 4.17e-05 | 4.91e-01 | 0.2446 |
27109 | ATP5S | S028 | Human | Liver | HCC | 1.96e-03 | 3.28e-01 | 0.2503 |
27109 | ATP5S | S029 | Human | Liver | HCC | 2.55e-09 | 5.33e-01 | 0.2581 |
27109 | ATP5S | C04 | Human | Oral cavity | OSCC | 2.42e-13 | 5.73e-01 | 0.2633 |
27109 | ATP5S | C21 | Human | Oral cavity | OSCC | 1.59e-35 | 8.38e-01 | 0.2678 |
27109 | ATP5S | C30 | Human | Oral cavity | OSCC | 3.58e-43 | 1.46e+00 | 0.3055 |
27109 | ATP5S | C38 | Human | Oral cavity | OSCC | 8.23e-07 | 7.03e-01 | 0.172 |
27109 | ATP5S | C43 | Human | Oral cavity | OSCC | 5.01e-13 | 3.25e-01 | 0.1704 |
27109 | ATP5S | C46 | Human | Oral cavity | OSCC | 1.55e-28 | 5.43e-01 | 0.1673 |
27109 | ATP5S | C51 | Human | Oral cavity | OSCC | 1.38e-02 | 2.36e-01 | 0.2674 |
27109 | ATP5S | C57 | Human | Oral cavity | OSCC | 1.48e-16 | 4.73e-01 | 0.1679 |
27109 | ATP5S | C06 | Human | Oral cavity | OSCC | 8.87e-05 | 8.09e-01 | 0.2699 |
27109 | ATP5S | C07 | Human | Oral cavity | OSCC | 3.46e-05 | 7.24e-01 | 0.2491 |
27109 | ATP5S | C08 | Human | Oral cavity | OSCC | 1.51e-36 | 7.41e-01 | 0.1919 |
27109 | ATP5S | C09 | Human | Oral cavity | OSCC | 2.22e-07 | 2.06e-01 | 0.1431 |
27109 | ATP5S | LN22 | Human | Oral cavity | OSCC | 1.04e-13 | 1.06e+00 | 0.1733 |
27109 | ATP5S | LN46 | Human | Oral cavity | OSCC | 4.64e-15 | 5.62e-01 | 0.1666 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5S | SNV | Missense_Mutation | c.230T>C | p.Val77Ala | p.V77A | Q99766 | protein_coding | tolerated(0.09) | probably_damaging(0.999) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ATP5S | SNV | Missense_Mutation | novel | c.250N>G | p.Arg84Gly | p.R84G | Q99766 | protein_coding | deleterious(0) | possibly_damaging(0.567) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD |
ATP5S | SNV | Missense_Mutation | novel | c.103T>C | p.Ser35Pro | p.S35P | Q99766 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
ATP5S | SNV | Missense_Mutation | novel | c.563T>G | p.Leu188Arg | p.L188R | Q99766 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
ATP5S | SNV | Missense_Mutation | novel | c.293A>G | p.Asp98Gly | p.D98G | Q99766 | protein_coding | tolerated(0.8) | benign(0.005) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ATP5S | SNV | Missense_Mutation | novel | c.401G>A | p.Cys134Tyr | p.C134Y | Q99766 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
ATP5S | SNV | Missense_Mutation | rs112164857 | c.589N>A | p.Leu197Ile | p.L197I | Q99766 | protein_coding | tolerated(0.8) | benign(0.001) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ATP5S | SNV | Missense_Mutation | rs755906483 | c.167G>A | p.Arg56His | p.R56H | Q99766 | protein_coding | deleterious(0.02) | possibly_damaging(0.875) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5S | SNV | Missense_Mutation | novel | c.94N>T | p.Leu32Phe | p.L32F | Q99766 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP5S | SNV | Missense_Mutation | novel | c.518N>T | p.Ala173Val | p.A173V | Q99766 | protein_coding | deleterious(0.03) | possibly_damaging(0.883) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |